top of page

Publications

2026

Proactive identification of candidates for newly approved targeted therapies using a clinical decision support program (Feldman et al. 2026) Caris

Characterization of ESR1 alterations in patients with breast and gynecologic cancers (Basu et al. 2026 Exact Sciences

Real-world clinical utility of comprehensive genomic and transcriptomic profiling in metastatic breast cancer (mBC) (Raghavendra 2026) BostonGene

2025

Mechanisms of resistance to trastuzumab deruxtecan in breast cancer elucidated by multi-omic molecular profiling (Sledge et al. 2025) Caris

HER2 alterations across solid tumors: implications for comprehensive testing (Ismail et al. 2025) Caris

Homologous Recombination Deficiency in Ovarian and Breast Cancers: Biomarkers, Diagnosis, and Treatment (Shah et al. 2025) Caris

Functional activation of the AKT-mTOR signalling axis in a real-world metastatic breast cancer cohort (Prasad et al. 2025) Ignite

Comprehensive genomic profiling of over 10,000 advanced solid tumors (De La O et al. 2025) Exact Sciences

Clinical and analytical validation of a combined RNA and DNA exome assay across a large tumor cohort (Yudina 2025) BostonGene

Personalized Circulating Tumor DNA Testing for Detection of Progression and Treatment Response Monitoring in Patients With Metastatic Invasive Lobular Carcinoma of the Breast (Foldi 2025) Natera Signatera

2024

Comprehensive molecular profiling identifies actionable biomarkers for patients from Thailand and the United Arab Emirates with advanced malignancies (Dawood et al. 2024) Caris

Proteomics based selection achieves complete response to HER2 therapy in HER2 IHC 0 breast cancer (Johnston et al. 2024) Ignite

Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast Cancer. (Shaw 2024) Natera Signatera

Association of post-operative ctDNA detection with outcomes of patients with early breast cancers (Cutts 2024) Natera Signatera

2023

Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial (Gallagher et al. 2023) Ignite

2022

Assessment of a cancer genomic profile test for patients with metastatic breast cancer (Fukada et al. 2022) FoundationOne

Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies (Wolf et al. 2022) Ignite

Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer (Shi et al. 2022) Ignite

Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study (Rea 2022) Hologic

2021

Next-Generation Sequencing-Directed Therapy in Patients with Metastatic Breast Cancer in Routine Clinical Practice (Bruzas et al. 2021) FoundationOne

Multi-omic molecular profiling guide's efficacious treatment selection in refractory metastatic breast cancer: a prospective phase II clinical trial (Pierobon et al. 2021) Ignite

Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial (Clark et al. 2021) Ignite

Abstract PS4-01: Clinical and genomic correlation of a CLIA certified organoid based functional test in breast cancer patients (Margossian 2021) Cure First (PARIS)

Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR+ Early-stage Breast Cancer for 10 Years of Endocrine Therapy (Noordhoek 2021) Hologic

2020

Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer (Sivapiragasam et al. 2020) FoundationOne

Real world data analysis of next generation sequencing and protein expression in metastatic breast cancer patients (Hempel et al. 2020) FoundationOne

The genomic landscape of metastatic breast cancer: Insights from 11,000 tumors (Rinaldi et al. 2020) FoundationOne

Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway (Heeke et al. 2020) Caris

Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial (Wolf et al. 2020) Ignite

2019

Biomarkers of Targeted Therapy and Immuno-Oncology in Cancers Metastatic to the Breast (Vranic et al. 2019) Caris

HER family protein expression and activation predicts response to combination T-DM1/pertuzumab in HER2+ patients in the I-SPY 2 TRIAL (Wulfkuhle et al. 2019) Ignite

2018

Molecular profiling of advanced breast cancer tumors is beneficial in assisting clinical treatment plans (Carter et al. 2018) Caris

Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL (Wulfkuhle et al. 2018) Ignite

bottom of page